Search Site
Related Products
TamoxifenTGF-β modulatory and PKC inhibitory effects


Catalog No. B5965
Size Price Stock Qty
500mg $50.00 In stock
1g $70.00 In stock
5g $210.00 In stock
10g $360.00 In stock

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure


Tamoxifen Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Tamoxifen Molarity Calculator



Chemical Properties

Cas No. 10540-29-1 SDF Download SDF
Canonical SMILES CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3
Formula C26H29NO M.Wt 371.51
Solubility >18.6mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


IC50: 5.5–10 μM

Transforming growth factor-β (TGF-β) is a growth factor which is capable of inhibiting prostate cell growth in vitro, and has apparent prostate cell growth regulatory roles in vivo. A second element of potential importance in regulating the growth of prostate cancer cells is the serine/threonine kinase, protein kinase C (PKC). PKC is a signaling enzyme of known importance in regulating the growth and/or differentiation of a variety of cell types; inhibition of its kinase activity is associated with loss of regulatory function. Tamoxifen is a drug known to have TGF-β modulatory and PKC inhibitory effects.

In vitro: IC50s for growth inhibition ranged from 5.5–10 μM, and were not affected by estrogen. Tamoxifen-mediated growth inhibition was not associated with induction of TGF-β. However, tamoxifen treatment was associated with inhibition of PKC, which was followed by induction of p21waf1/cip1, Rb dephosphorylation, and G1/S phase cell cycle arrest [1].

In vivo: The tumor cell kinetics of MCF-7 human breast carcinoma xenografts grown in nude mice can be significantly altered by hormonal manipu lation. Tamoxifen treatment or E2 deprivation resulted in an approximate doubling of the Tpol and an approximately 40% reduction in labeling index as compared to E2-stimulated tumors. An increase in cell loss rate was calculated for both tamoxifen treatment and E2 deprivation [2].

Clinical trial: Tamoxifen reduces the risk of recurrence and death from breast cancer when given as adjuvant therapy, and it provides effective palliation for metastatic breast cancer. Its use is therefore indicated for both premenopausal and postmenopausal women having estrogen-receptor–positive invasive breast cancer [3].

[1] Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC.  Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate. 1998 Sep 15;37(1):51-9.
[2] Jann N.  Sarkaria, David F. C. Gibson, V. Craig Jordan, John F. Fowler, Mary J. Lindstrom, and
R.  Timothy Mulcahy. Tamoxifen-induced Increase in the Potential Doubling Time of MCF-7 Xenografts as Determined by Bromodeoxyuridine Labeling and Flow Cytometry. CANCER RESEARCH 5.1. 4413-1417, September 15, 1993.
[3] Osborne CK.  Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18.